Cargando…

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

BACKGROUND: Previous randomized studies have demonstrated that fesoterodine significantly improves the Overactive Bladder (OAB) symptoms and their assessment by patients compared with tolterodine extended-release (ER). This study aimed to assess the effect of aging and dose escalation on patient-rep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castro-Diaz, David, Miranda, Pilar, Sanchez-Ballester, Francisco, Lizarraga, Isabel, Arumí, Daniel, Rejas, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514115/ https://www.ncbi.nlm.nih.gov/pubmed/22834707 http://dx.doi.org/10.1186/1471-2490-12-19

Ejemplares similares

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER
por: Kaplan, S A, et al.
Publicado: (2014)

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2013)

Role of fesoterodine in the treatment of overactive bladder
por: Mansfield, Kylie J
Publicado: (2009)

Efficacy of tolterodine in children with overactive bladder
por: Koç, Başak, et al.
Publicado: (2020)

Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain
por: Peral, Carmen, et al.
Publicado: (2016)

Fesoterodine for the treatment of urinary incontinence and overactive bladder
por: Ellsworth, Pamela
Publicado: (2009)

Comparison of solifenacin and fesoterodine in treatment of overactive bladder
por: Ercan, Önder, et al.
Publicado: (2015)

Overactive bladder, differential diagnosis, and clinical utility of fesoterodine
por: Wyndaele, Jean-Jacques
Publicado: (2012)

Update on tolterodine extended-release for treatment of overactive bladder
por: Omotosho, Tola, et al.
Publicado: (2010)

Safety and Tolerability of Fesoterodine in Older Adult Patients with Overactive Bladder
por: Heesakkers, John, et al.
Publicado: (2022)

Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder
por: Rajabalaya, Rajan, et al.
Publicado: (2016)

Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder
por: Cardozo, Linda, et al.
Publicado: (2010)

The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
por: Ulahannan, Danny, et al.
Publicado: (2009)

Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women
por: Aziminekoo, Elham, et al.
Publicado: (2014)

Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder
por: Kaga, Kanya, et al.
Publicado: (2020)

Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
por: Morris, Vikky, et al.
Publicado: (2014)

The effect of extended release tolterodine used for overactive bladder treatment on female sexual function
por: Zachariou, Athanasios, et al.
Publicado: (2017)

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study
por: Wyndaele, J-J, et al.
Publicado: (2009)

NGF and HB-EGF: Potential Biomarkers that Reflect the Effects of Fesoterodine in Patients with Overactive Bladder Syndrome
por: Kim, Soo Rim, et al.
Publicado: (2015)

Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
por: Heesakkers, John, et al.
Publicado: (2017)

Effects of Bladder Training and/or Tolterodine in Female Patients with Overactive Bladder Syndrome: A Prospective, Randomized Study
por: Song, Cheryn, et al.
Publicado: (2006)

Dissimilar Effects of Tolterodine on Detrusor Overactivity in Awake Rats with Chemical Cystitis and Partial Bladder Outlet Obstruction
por: Jin, Long-Hu, et al.
Publicado: (2011)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014)

Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
por: Sano, Yamato, et al.
Publicado: (2023)

The combination of herbal medicine Weng-li-tong with Tolterodine may be better than Tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial
por: Xiao, Dong-dong, et al.
Publicado: (2016)

Comparison of micro-radiofrequency therapy and tolterodine for the treatment of newly diagnosed overactive bladder: A retrospective cohort study
por: Tang, Min, et al.
Publicado: (2023)

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model
por: Arlandis-Guzman, Salvador, et al.
Publicado: (2011)

What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine
por: Wagg, Adrian S., et al.
Publicado: (2021)

AB078. Disease correlation and effects of pelvic floor muscle training on tolterodine based treatment for female primary overactive bladder syndrome
por: Huang, Xiao, et al.
Publicado: (2016)

Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model
por: Biardeau, Xavier, et al.
Publicado: (2017)

Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo
por: Van Kerrebroeck, Philip EV, et al.
Publicado: (2009)

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
por: Herschorn, Sender, et al.
Publicado: (2018)

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)
por: Staskin, David, et al.
Publicado: (2017)

Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study
por: Kakizaki, Hidehiro, et al.
Publicado: (2020)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Tolterodine extended release is well tolerated in older subjects
por: Griebling, T L, et al.
Publicado: (2009)

On the Absolute Stereochemistry of Tolterodine: A Circular Dichroism Study
por: Górecki, Marcin, et al.
Publicado: (2019)

Postmenopausal overactive bladder
por: Tomaszewski, Jacek
Publicado: (2014)

Protocol for a phase II, open-label exploratory study investigating the efficacy of fesoterodine for treatment of adult patients with spinal cord injury suffering from neurogenic detrusor overactivity for amelioration of autonomic dysreflexia
por: Walter, Matthias, et al.
Publicado: (2018)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
por: Al-Ghazo, Mohammed A., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_17ma3o6kmqgc6ms488lpv6hpk7